Beyond market averages, investors looking for exceptional returns turn to stock picking. Skillful choices in individual stocks have the power to substantially increase your wealth.
The price of Fulcrum Therapeutics Inc (NASDAQ: FULC) closed at $11.31 in the last session, down -0.26% from day before closing price of $11.34. In other words, the price has decreased by -$0.26 from its previous closing price. On the day, 0.93 million shares were traded. FULC stock price reached its highest trading level at $11.761 during the session, while it also had its lowest trading level at $11.13.
Ratios:
We take a closer look at FULC’s different ratios to gain a better understanding of the stock. For the most recent quarter (mrq), Quick Ratio is recorded 17.70 and its Current Ratio is at 17.70. In the meantime, Its Debt-to-Equity ratio is 0.04 whereas as Long-Term Debt/Eq ratio is at 0.02.
On July 29, 2025, H.C. Wainwright Upgraded its rating to Buy which previously was Neutral and also upped its target price recommendation from $4 to $12.
Leerink Partners Upgraded its Market Perform to Outperform on May 23, 2025, while the target price for the stock was maintained at $12.
Insider Transactions:
An investor can also benefit from insider trades by learning what management is thinking about the future direction of stock prices. A recent insider transaction in this stock occurred on Dec 15 ’25 when Oltmans Curtis Gale sold 3,452 shares for $12.92 per share. The transaction valued at 44,600 led to the insider holds 10,252 shares of the business.
CURTIS G OLTMANS bought 3,452 shares of FULC for $44,876 on Dec 15 ’25. On Dec 08 ’25, another insider, RA CAPITAL MANAGEMENT, L.P., who serves as the 10% Owner of the company, sold 4,175,139 shares for $13.98 each. As a result, the insider received 58,377,021 and left with 6,053,960 shares of the company.
Valuation Measures:
Investors should consider key stock statistics when deciding whether to invest or divest. In the wake of the recent closing price, FULC now has a Market Capitalization of 746124032 and an Enterprise Value of 418445536.
Stock Price History:
The Beta on a monthly basis for FULC is 3.20, which has changed by 1.226378 over the last 52 weeks, in comparison to a change of 0.15196204 over the same period for the S&P500. Over the past 52 weeks, FULC has reached a high of $15.74, while it has fallen to a 52-week low of $2.32. The 50-Day Moving Average of the stock is 8.40%, while the 200-Day Moving Average is calculated to be 53.21%.
Shares Statistics:
According to the various share statistics, FULC traded on average about 1.30M shares per day over the past 3-months and 877340 shares per day over the past 10 days. A total of 65.97M shares are outstanding, with a floating share count of 59.86M. Insiders hold about 9.27% of the company’s shares, while institutions hold 67.44% stake in the company. Shares short for FULC as of 1765756800 were 2994328 with a Short Ratio of 2.31, compared to 1763078400 on 3564671. Therefore, it implies a Short% of Shares Outstanding of 2994328 and a Short% of Float of 6.0700003.
Earnings Estimates
. The current assessment of Fulcrum Therapeutics Inc (FULC) involves the perspectives of 10.0 analysts closely monitoring its market dynamics.The consensus estimate for the next quarter is -$0.29, with high estimates of -$0.21 and low estimates of -$0.33.
Analysts are recommending an EPS of between -$1.13 and -$1.21 for the fiscal current year, implying an average EPS of -$1.17. EPS for the following year is -$1.2, with 10.0 analysts recommending between -$0.85 and -$1.52.
